A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: An Eastern Cooperative Oncology Group study (E1587)

Cancer

Volumn 82, Issue 2, 1998, Pages 292-300

  Chang, Alex Y ^a   Kim, KyungMann ^b   Boucher, Hélène ^c   Bonomi, Philip ^d   Stewart, James A ^e   Karp, Daniel D ^f   Blum, Ronald H ^g  

^a Interlakes Oncology and Hematology PC   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Echinomycin; Etoposide; Nonsmall cell lung carcinoma; Trimetrexate

Indexed keywords

CISPLATIN; ECHINOMYCIN; TRIMETREXATE;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ECHINOMYCIN; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTERCALATING AGENTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; REMISSION INDUCTION; SURVIVAL RATE; TRIMETREXATE;

EID: 0031965575     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980115)82:2<301::AID-CNCR8>3.0.CO;2-T     Document Type: Article

References (25)

1. Ihde DC, Pass H, Glastein E. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. Philadelphia: J. B. Lippincott, 1993:723-58.
2. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
3. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-13.
4. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
5. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, et al. A comparison of best supportive care to two regimens of combination chemotherapy in the management of advanced non-small cell lung cancer (NSCLC): a report of a Canadian multicenter trial. J Clin Oncol 1988;6:633-41.
6. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990;8:1556-62.
7. Huang CH, Mirabelli CK, Mong S, Crooke ST. Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). Cancer Res 1983;43:2718-24.
8. Foster BJ, Clagett-Carr K, Shoemaker DD, Suffness M, Plowman J, Trissel LA, et al. Echinomycin: the first bifunctional intercalating agent in clinical trials. Invest New Drugs 1985; 3:403-10.
9. O'Dwyer PJ, Shoemaker DD, Plowman J, Cradock J, Grillo-Lopez A, Leyland-Jones B. Trimetrexate: a new antifol entering clinical trials. Invest New Drugs 1985;3:71-5.
10. Ohnoshi T, Ohnuma T, Takahashi I, Scanlon K, Kamen BA, Holland JF. Establishment of methotrexate resistant human acute lymphoblastic leukemic cells in culture and effects of folate antagonists. Cancer Res 1982;42:1655-60.
11. Seitz DE. Trimetrexate: a critical appraisal of the phase II clinical trial experience/evidence of drug discovery-clinical development disjunction. Cancer Invest 1994;12:657-61.
12. Conti JA, Kemeny N, Seites K, Goker E, Tong W, Andre M, et al. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994;12:695-700.
13. Oken MM, Creech RM, Tormey DC, Morton J, Davis TE, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
14. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34:585-612.
15. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952;47:583-612.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1970.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
19. Fossella FV, Winn RJ, Holoye PY, Hallinan B, Raber MN, Hoelzer K, et al. Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs 1992;10:331-5.
20. Mauron J. Clinical response to trimetrexate as sole therapy for non-small cell lung cancer. Semin Oncol 1988;15(Suppl 2):17-21.
21. Kris MG, D'Acquisto RW, Gralla RJ, Burke MT, Marks LD, Fanucchi MP, et al. Phase II trial of trimetrexate in patients with stage III and IV non-small cell lung cancer. Am J Clin Oncol 1989;12:24-6.
22. Bonomi P, Finkelstein D, Chang A, Ruckdeschel J. Decreasing response rates in Eastern Cooperative Oncology Group (ECOG) stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1991;10:261.
23. Bonomi P, Finkelstein D, Chang A. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: an Eastern Cooperative Oncology Group study. Am J Clin Oncol 1994;17:215-7.
24. Bunn PA Jr. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin Oncol 1994;21(Suppl 6):49-59.
25. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993;329:1790-6.